论文部分内容阅读
目的探讨检测人附睾蛋白-4于卵巢癌患者的危险性判断及评估预后的临床意义。方法回顾湖北省十堰市白浪开发区社区卫生服务中心医院2009年5月1日—2011年5月1日期间卵巢癌患者的病例资料,并进行电话随访。根据患者预后分为死亡组和存活组,通过组间单因素比较及多因素logistic回归分析等方法评价各因素与患者不良预后的相关性。结果共调查124例患者,平均年龄(53.54±7.15)岁,死亡组和存活组分别为55(44.4%)和69(55.6%)例。与存活组相比,死亡组的绝经期女性所占比、已生育女性所占比、家族遗传史所占比、总胆固醇、糖链抗原125、癌胚抗原、人附睾蛋白-4与患者不良预后有显著相关性。将该指标引入多因素logistic回归分析,得出最佳线性方程由绝经期所占比、家族遗传史所占比、总胆固醇、糖链抗原125、人附睾蛋白-4构成。再将上述相关危险因素行受试者工作特征(ROC)曲线检验并计算曲线下面积,判断相关危险因素的检验效能,纳入人附睾蛋白-4后曲线下面积为0.835,曲线下面积较未纳入时显著增加。结论人附睾蛋白-4升高将增加卵巢癌患者不良预后的风险,将该指标纳入卵巢癌的评测体系可进一步增强评估该病患者高危风险的能力。
Objective To investigate the clinical significance of detecting the risk of human epididymis-4 in patients with ovarian cancer and assess the prognosis. Methods The data of patients with ovarian cancer from May 1, 2009 to May 1, 2011 in Bailang Development Community Health Service Center Hospital of Shiyan City, Hubei Province were retrospectively reviewed and followed up by telephone. According to the prognosis of patients, the patients were divided into death group and survival group. The correlation between each factor and adverse prognosis was evaluated by single factor comparison and multivariate logistic regression analysis. Results A total of 124 patients were investigated, with an average age of 53.54 ± 7.15 years, with 55 (44.4%) and 69 (55.6%) death and survivors, respectively. Compared with the survival group, the death group of menopausal women, the proportion of women who have had children, the proportion of family history, total cholesterol, carbohydrate antigen 125, carcinoembryonic antigen, human epididymis-4 and patients with poor The prognosis was significantly correlated. The index was introduced into multivariate logistic regression analysis, the best linear equation derived from the menopausal period, the proportion of family history, total cholesterol, sugar chain antigen 125, human epididymal protein -4 constitution. Then the relevant risk factors were tested by ROC curves and the area under the curve was calculated to test the performance of the relevant risk factors. The area under the curve of the epididymal protein-4 posterior curve was 0.835, and the area under the curve was not included When significantly increased. CONCLUSIONS: Elevated human epididymal protein-4 may increase the risk of adverse prognosis in patients with ovarian cancer. The inclusion of this indicator in the ovarian cancer evaluation system may further enhance the ability to assess the high-risk patients’ risk.